A week after its new drug application for one antibiotic was rejected by the Food and Drug Administration, Nabriva Therapeutics has filed an application seeking approval for a second experimental antibiotic in Europe.
Nabriva (NASDAQ: NBRV) is seeking approval from the European Medicines Agency for both the intravenous and oral formulations of Lefamulin as a treatment of community-acquired pneumonia in adults. If the application is approved, Nabriva — which is based in Dublin, Ireland, and has…
